Mesenchymal Stem Cells Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Mesenchymal Stem Cells Market Analysis

The Mesenchymal Stem Cells Market size is estimated at USD 4.09 billion in 2024, and is expected to reach USD 7.29 billion by 2029, growing at a CAGR of 12.29% during the forecast period (2024-2029).

The mesenchymal stem cells (MSC) market is experiencing significant growth driven by several key factors. The expansion of research and development, alongside clinical trials for mesenchymal stem cell-based products, is an important contributor. Additionally, the rising applications of mesenchymal stem cells (MSCs) and increasing competition among key market players are propelling the market’s growth. The growing adoption of mesenchymal stem cell treatments for age-related ailments, the rising prevalence of chronic disorders, the rapid surge in cancer incidences, and the utilization of mesenchymal stem cells for stroke treatment and brain repair are expected to boost market growth during the forecast period.

Moreover, an exponential rise in MSC-based research and its implications in regenerative medicine fuel the market's growth. For instance, a report published by the Stem Cell Research and Therapy Journal in May 2024 mentioned that the phase II randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy of intrathecal mesenchymal stem cell-neural progenitors (MSC-NPs) in patients with progressive multiple sclerosis (MS). It showed promising improvements in walking speed, endurance, bladder function, and brain atrophy reduction, particularly in patients with higher disability levels.

While the primary outcome measure, Expanded Disability Status Scale Plus (EDSS Plus), did not show a significant difference between the MSC-NP and placebo groups, exploratory subgroup analyses indicated notable improvements in mobility and bladder function. These findings suggested promising therapeutic potential for patients with progressive multiple sclerosis. These results underscored the commercial potential and market growth of MSC-based therapies, particularly for conditions lacking effective treatments, thus attracting investment and development in the market.

The rising prevalence of chronic disorders and the rapid surge in cancer incidence are driving the growth of the market globally. For instance, according to a report published by the World Health Organization in February 2024, in 2022, over 20 million new cancer cases were reported, and 53.5 million individuals were living within five years of a cancer diagnosis. Approximately 20% of the global population is expected to develop cancer at some point in their lifetime.

The rise in cases of liver disease is also expected to propel the growth of the market. For instance, according to a report published by the government of the United Kingdom in April 2024, hospital admission rates for liver diseases increased to 155.2 per 100,000 people in the financial year ending 2023. The significant increase in cases, such as the 27,085 admissions for alcoholic liver disease, underscores the urgent need for advanced therapeutic options, thereby driving investment and development in mesenchymal stem cell-based treatments for liver regeneration and repair. Therefore, an increase in chronic diseases is estimated to boost market growth.

In addition, the constant development of stem cell therapies is projected to propel investments in the market with large-scale operational entities targeting small or emerging players with an acquisition strategy to expand their market presence. For instance, in August 2022, AGC Biologics partnered with RoosterBio Inc. to create an end-to-end solution for developing and producing human mesenchymal stem cells and exosome therapeutics. Therefore, the increasing advancements in stem cell therapies are driving market investments, characterized by major operational entities acquiring smaller players to enhance their market influence, exemplified by partnerships focused on developing and producing human mesenchymal stem cells and exosome therapeutics.

Therefore, owing to the abovementioned factors, the market is anticipated to grow over the forecast period. However, the need for standardized and regulated delivery of stem cell therapy, coupled with ethical concerns associated with human mesenchymal stem cell therapy, is expected to impede market growth.

Mesenchymal Stem Cells Market Trends

Cardiovascular Diseases Segment is Expected to Witness a Significant Growth Over the Forecast Period

Mesenchymal Stem Cells Industry Segmentation

As per the scope of the report, mesenchymal stem cells (MSCs) are a type of multipotent stem cell that can differentiate into a variety of cell types, such as cartilage cells (chondrocytes), bone cells (osteoblasts), muscle cells (myocytes), and fat cells (adipocytes). 

The mesenchymal stem cells market is segmented into products and services, type, source, indication, application, and geography. The products and services segment is further divided into products and services. The products segment is subdivided into kits, media and reagents, cells and cell lines, and other products. By type, the market is segmented into autologous and allogeneic. The source segment is further divided into adipose tissue, bone marrow, cord blood, fetal liver, and others. The indication segment is further divided into bone and cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, graft vs host diseases, and others. The application segment is divided into disease modeling, drug development and discovery, stem cell banking, tissue engineering, toxicology studies, and others. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for all the above segments.